<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02510781</url>
  </required_header>
  <id_info>
    <org_study_id>BJ307-Neo02</org_study_id>
    <nct_id>NCT02510781</nct_id>
  </id_info>
  <brief_title>A Study on Neoadjuvant Therapy for Her-2 Positive Breast Cancer and the Prognosis by Detecting CTCs</brief_title>
  <official_title>A Study on Neoadjuvant Therapy for Her-2 Positive Breast Cancer and the Prognosis Detecting Circulating Tumor Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Affiliated to Military Medical Science, Beijing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Affiliated to Military Medical Science, Beijing</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Docetaxel plus carboplatin and trastuzumab has been a standard treatment for patients with
      human epidermal growth factor receptor-2（HER-2）positive. The investigators witnessed a higher
      pathological complete remission(pCR) rate but no obvious increase in cardiac toxicity when
      used the anthracycline instead of carboplatin. The investigators expect to carry out a large
      sample size clinical research to optimize the existing therapeutic regimen
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pathological complete response rate</measure>
    <time_frame>up to one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical response rate</measure>
    <time_frame>up to one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Event</measure>
    <time_frame>up to one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>A group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>docetaxel+carboplatin+trastuzumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Epirubicin+docetaxel+trastuzumab-docetaxel+trastuzumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <description>75mg/m2 d1 evry 21days</description>
    <arm_group_label>B group</arm_group_label>
    <other_name>pharmorubicin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>75mg/m2 d1 evry 21days</description>
    <arm_group_label>A group</arm_group_label>
    <arm_group_label>B group</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>6mg/kg(loading dosage is 8mg/kg)</description>
    <arm_group_label>A group</arm_group_label>
    <arm_group_label>B group</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Area Under Curve(AUC)=6 d1 evry 21days</description>
    <arm_group_label>A group</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18≤aged＜70

          -  pathologic diagnosis of invasive breast cancer，staging ii to iii，the diameters≥2cm
             indicated by MRI or axillary lymph node（+）

          -  Immunohistochemical（IHC） positive for 3+ or FISH（+）

          -  clear hormone receptor（HR） status

          -  Eastern cooperative oncology group(ECOG)=0/1

          -  LVEF≥55%

          -  pathologic grading of Miller and Payne

          -  screening laboratory values with the following parameters：absolute neutrophils
             acount：≥1500/mm3,total bilirubin:≤2.0×ULM,Aspartate transaminase
             (AST)/ALT≤2.5×ULM,platelet≥80000/mm3，serum creatinine≤1.5×ULM

          -  no pregnant or nursing

          -  signed Informed consent forms

        Exclusion Criteria:

          -  prior exposure to any treatments for breast cancer

          -  inflammatory/Bilateral/IV stage breast cancer

          -  poor physical condition

          -  pregnant or nursing

          -  Cardiac risk（Congestive heart failure、arrhythmia、myocardial infarct、Refractory
             hypertension（systolic pressure＞180mmHg/diastolic pressure＞100mmHg））

          -  any other cancer within 5 years prior to screening with the exception of cervical
             carcinoma and non melanoma skin cancer

          -  Allergic to chemotherapy drugs
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>zefei jiang, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academy MMS,China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>tao wang, Ph.D</last_name>
    <phone>8610-66947172</phone>
    <email>wangtao733073@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>zefei jiang, Ph.D</last_name>
    <phone>8610-66947171</phone>
    <email>jiangzf@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital affiliated to military medical science</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>tao wang, Ph.D</last_name>
      <phone>8610-66947172</phone>
      <email>wangtao733073@163.com</email>
    </contact>
    <contact_backup>
      <last_name>zefei jiang, ph.d</last_name>
      <phone>8610-66947171</phone>
      <email>zfjiang@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2015</study_first_submitted>
  <study_first_submitted_qc>July 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2015</study_first_posted>
  <last_update_submitted>July 27, 2015</last_update_submitted>
  <last_update_submitted_qc>July 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

